Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2009-08-24
2011-10-11
Jiang, Dong (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S143100, C530S387100, C530S350000, C530S351000
Reexamination Certificate
active
08034341
ABSTRACT:
Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.
REFERENCES:
patent: 6756481 (2004-06-01), Chirica et al.
patent: 2003/0157105 (2003-08-01), Carton et al.
patent: WO 01/18051 (2001-03-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 02/29060 (2002-04-01), None
patent: WO 02/097048 (2002-12-01), None
Denarello, C.A. Interleukin-1 in disease. Keio J Med. Sep. 1994;43(3):131-6.
Broberg, et al. (2002)J. Interferon Cytokine Res. 22:641-651, “Herpes Simplex Virus Type 1 Infection Induces Upregulation of Interleukin-23 (p19) mRNA Expression in Trigeminal Ganglia of BALB/c Mice”.
Cannistra and Niloff (1996)New Engl. J. Med. 334:1030-1038, “Cancer of the Uterine Cervix”.
Coussens and Werb (2002)Nature420:860-867, “Insight review articles: Inflammation and cancer”.
Cooper, et al. (2002)J. Immunol. 168:1322-1327, “Mice Lacking Bioactive IL-12 Can Generate Protective, Antigen-Specific Cellular Responses to Mycobacterial Infection Only if the IL-12 p40 Subunit Is Present”.
Cua, et al. (2003)Nature421:744-748, “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain”.
Dejong, et al. (1993)Genes Dev. 7(11):2220-34, (abstract only), “A single cDNA, hTFIIA/alpha, encodes both the p35 and p19 subunits of human TFIIA”.
Elkins, et al. (2002)Infection Immunity70:1936-1948, “In Vivo Clearance of an Intracellular Bacterium,Francisella tularensisLVS, Is Dependent on the p40 Subunit of Interleukin-12 (IL-12) but Not on IL-12 p70”.
Enzinger and Mayer (2003)New Engl. J. Med. 349:2241-2252, “Esophageal Cancer”.
Farrar, et al. (1999)J. Immunol. 162:2842-2849, “Cancer Dormancy. VII. A Regulatory Role for CD8+T Cells and IFN-γ in Establishing and Maintaining the Tumor-Dormant State”.
Fischer, et al. (1997)Nature Biotechnol. 15:142-145, “A bioactive designer cytokine for human hematopoietic progenitor cell expansion”.
Forastiere, et al. (2001)New Engl. J. Med. 345:1890-1900, “Head and Neck Cancer”.
Frucht (2002)Sci STKE2002, E1-E3, “IL-23: A Cytokine That Acts on Memory T Cells”.
Izbicki, et al. (1997)New Engl. J. Med. 337:1188-1194, “Prognostic Value of Immunohistochemically Identifiable Tumor Cells in Lymph Nodes of Patients with Completely Resected Esophageal Cancer”.
Le, et al. (2001)J. Immunol. 167:6765-6772, “Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12”.
Lo, et al. (2003)J. lmmunol. 171:600-607, “Antitumor and Antimetastatic Activity of IL-23”.
Lynch and Chapelle (2003)New Engl. J. Med. 348:919-932, “Hereditary Colorectal Cancer”.
Oppmann, et al. (2000)Immunity13:715-725, “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12”.
Osborne (1998)New Engl. J. Med. 339:1609-1618, “Tamoxifen In the Treatment of Breast Cancer”.
Parham, et al. (2002)J. Immunol. 168:5699-5708, “A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R”.
Peters, et al.(1998)J. Immunol. 161:3575-3581, “In Vivo and In Vitro Activities of the gp130-Stimulating Designer Cytokine Hyper-IL-6”.
Pirhonen, et al. (2002)J. Immunol. 169:5673-5678, “Regulation of Virus-Induced IL-12 and IL-23 Expression in Human Macrophages”.
Rakemann, et al. (1999)J. Biol. Chem. 274:1257-1266, “The Designer Cytokine Hyper-Interleukin-6 Is a Potent Activator of STAT3-dependent Gene Transcription in Vivo and in Vitro”.
Ramirez-Montagut, et al. (2003)Oncogene22:3180-3187, “Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity”.
Sawaya, et al. (2003)New Engl. J. Med. 349:1501-1509, “Risk of Cervical Cancer Associated with Extending the Interval between Cervical-Cancer Screenings”.
Ugai, et al. (2003)Cancer Gene Therapy10:771-778, “Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects”.
Wiekowski, et al. (2001)J. Immunol. 166:7563-7570, “Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death”.
McClanahan Terrill K.
Oft Martin
Bellomy Gregory R.
Jiang Dong
Schering Corporation
LandOfFree
Methods of inhibiting tumor growth using blocking antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting tumor growth using blocking antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting tumor growth using blocking antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4277849